Salona Global Finalizes Name Change to Evome Medical Technologies to Reflect Turn Around and New Innovation Focus; Restructures Board of Directors
Salona Global Finalizes Name Change to Evome Medical Technologies to Reflect Turn Around and New Innovation Focus; Restructures Board of Directors
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (the "Company") (TSXV:SGMD), is pleased to announce its corporate name change to Evome Medical Technologies Inc. on January 22, 2024, and trading of the Company's common shares on the TSX Venture Exchange will commence under the ticker symbol "EVMT" on January 22, 2024. The name change reflects the Company's commitment as a high-tech physical therapy medical device company. Appointed in June 2023, Mr. Seckler has successfully implemented strategic imperatives that have resulted in the establishment of the new Evome Medical Technologies Inc:
纽约,2024年1月18日(环球新闻专线)——萨罗纳环球医疗器械公司( “公司”)(多伦多证券交易所股票代码:SGMD)欣然宣布于2024年1月22日将其公司更名为Evome Medical Technologies Inc.,并在该公司的普通股上市多伦多证券交易所风险交易所将于2024年1月22日上市,股票代码为 “EVMT”。更名反映了公司作为高科技物理治疗医疗器械公司的承诺。塞克勒先生于2023年6月被任命,成功实施了战略要务,从而成立了新的Evome Medical Technologies Inc.:
- 18.5% revenue growth for the quarter ending September 30, 2023 (compared to the previous quarter), management expects revenue growth to continue into 2024.
- 29% gross profit growth for the quarter ending September 30, 2023 (compared to the previous quarter), management expects gross profit growth to continue into 2024.
- Generated positive Adjusted EBITDA (defined below) of $749,425 for the quarter ending September 30, 2023, management expects positive Adjusted EBITDA growth to continue into 2024.
- Announced plans to launch two new Biodex products, the SpaceTek Knee (November 17, 2023) and the Biodex Reactive Step Trainer (December 18, 2023), into the private physical therapy market that has ten times the amount of customers than the institutional market current Biodex products are marketed to.1
- Reduced Biodex acquisition debt by US$428,237 in the third quarter and extended the balance of the debt until July 2025 pursuant to the previously announced forbearance agreement.
- Restructured the management team and Board of Directors with a focus on innovation focused managers and board members with the most recent change coming from Leslie Cross retiring from the Board of Directors.
- Refocused the capital markets communication with new investor presentation () in advance of attending the CEM AlphaNorth Capital Event in Nassau, Bahamas from January 19-21, 2024.
- 截至2023年9月30日的季度(与上一季度相比)收入增长18.5%,管理层预计收入增长将持续到2024年。
- 管理层预计,截至2023年9月30日的季度毛利增长29%(与上一季度相比),毛利增长将持续到2024年。
- 截至2023年9月30日的季度,调整后息税折旧摊销前利润为正(定义见下文)of 749,425美元,管理层预计调整后息税折旧摊销前利润的正增长将持续到2024年。
- 宣布计划向私人物理治疗市场推出两款新的Biodex产品,即SpaceTek Knee(2023年11月17日)和Biodex Reactive Step Trainer(2023年12月18日),该市场的客户数量是目前Biodex产品销售的机构市场的十倍。1
- 根据previously 宣布的宽限协议,在第三季度将Biodex的收购债务减少了428,237美元,并将debt 的余额延长至2025年7月。
- 重组了管理团队和董事会,重点关注创新的经理和董事会成员,最近的变动来自莱斯利·克罗斯从董事会退休。
- 在参加2024年1月19日至21日在巴哈马拿骚举行的CEM AlphaNorth Capital活动之前,通过新的投资者演讲()重新调整了资本市场沟通的重点。
Mr. Seckler expressed, "Now that we generated revenue growth and Adjusted EBITDA, we are prioritizing the creation of new products and strengthening our ability to innovate in the rapidly expanding physical rehabilitation and recovery market." In closing, Mr. Seckler stated, "Our focus is on product innovation, and we are structuring Evome to be in a position for continuous growth. The recent changes, such as reducing debt, adding new distribution agreements, and the restructuring of the board, solidify our commitment to sustained success."
塞克勒表示:“现在我们实现了收入增长和调整后的息税折旧摊销前利润,我们将优先开发新产品并增强我们在快速扩张的物理康复和康复市场的创新能力。”最后,塞克勒先生表示:“我们的重点是产品创新,我们正在构建Evome以使其能够持续增长。最近的变化,例如减少债务、增加新的分销协议以及重组董事会,巩固了我们对持续成功的承诺。”
For more information please contact:
欲了解更多信息,请联系:
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: Info@Salonaglobal.com
迈克·塞克勒
首席执行官
电话:1 (800) 760-6826
电子邮件:Info@Salonaglobal.com
Non-GAAP Measures
非公认会计准则指标
This press release refers to "Adjusted EBITDA" which is a non-GAAP and non-IFRS financial measure that does not have a standardized meaning prescribed by GAAP or IFRS. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. This non-GAAP financial measure assists the Company's management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition plans that are fundamentally different from the ongoing operating plans of the Company. The Company's management also believes that presenting this measure allows investors to view the Company's performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
本新闻稿提及 “调整后息税折旧摊销前利润”,这是一项非公认会计准则和非国际财务报告准则财务measure,not 具有公认会计原则或国际财务报告准则规定的标准化含义。Company 对这份财务measure 的呈现方式可能无法与其他公司使用的类似标题的measures 相提并论。这种非公认会计准则财务指标有助于公司management 比较其一段时间内的经营业绩,因为某些项目可能obscure 基本业务趋势,难以比较长期业绩,as 它们的性质和/或规模,发生频率不一致或与离散有关acquisition 计划与Company 的持续运营计划有根本的不同。公司管理层还认为,提出这项衡量标准允许investors 使用与公司uses 评估其财务和业务业绩及趋势相同的衡量标准来查看公司的业绩。
"Adjusted EBITDA" is defined as net loss excluding interest expense, provision for income taxes, depreciation of property and equipment, amortization of right-of-use asset, amortization of intangible asset, foreign exchange (loss) gain, other income, provision for impairment, change in fair value of contingent consideration, transaction costs, and stock-based compensation.
“调整后息税折旧摊销前利润” 定义为净亏损,不包括利息支出、收入准备金taxes、财产和设备折旧、使用权资产摊销、摊销of 无形资产、外汇(亏损)收益、其他收入、减值准备金、或有对价公允价值change、交易成本和股票compensation。
The following table provides reconciliation between net income (loss) and Adjusted EBITDA:
下表提供了净收益(亏损)与调整后息税折旧摊销前利润之间的对账:
For the three months ended | For the nine months ended | |||||||||||||||
September 30 | September 30 | September 30 | September 30 | |||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net Loss | $ | 2,988,468 | $ | (9,801,081) | $ | 209,881 | $ | (14,045,048) | ||||||||
Interest Expense | 641,466 | 196,788 | 1,373,998 | 432,005 | ||||||||||||
Provision for income taxes | 9,561 | (69,033) | 48,105 | (214,750) | ||||||||||||
Depreciation of property and equipment | 273,092 | 172,654 | 722,422 | 313,594 | ||||||||||||
Amortization of right-of-use asset | 518,873 | 133,991 | 1,441,014 | 304,027 | ||||||||||||
Amortization of intangible asset | 392,615 | 254,706 | 1,093,714 | 718,716 | ||||||||||||
Foreign exchange (loss) gain | 80 | 62,971 | (4,438) | 66,904 | ||||||||||||
Other income | (1,185,110) | (1,252) | (2,000,671) | (1,300) | ||||||||||||
Provision for impairment | - | - | - | 5,527,913 | ||||||||||||
Change in fair value of earnout consideration | - | - | (1,165,697) | 2,451,600 | ||||||||||||
Change in fair value of contingent consideration | (3,542,325) | 8,053,337 | (3,269,230) | 2,659,329 | ||||||||||||
Transaction costs | 72,839 | 838,957 | 607,151 | 2,407,366 | ||||||||||||
Severance Expenses | 315,569 | - | 544,318 | - | ||||||||||||
Stock based compensation | 264,637 | 378,683 | 1,001,733 | 1,306,341 | ||||||||||||
Adjusted EBITDA | $ | 749,765 | $ | 220,721 | $ | 602,300 | $ | 1,926,697 |
在结束的三个月中 | 在结束的九个月中 | |||||||||||||||
9 月 30 日 | 9 月 30 日 | 9 月 30 日 | 9 月 30 日 | |||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
净亏损 | $ | 2,988,468 | $ | (9,801,081) | $ | 209,881 | $ | (14,045,048) | ||||||||
利息支出 | 641,466 | 196,788 | 1,373,998 | 432,005 | ||||||||||||
所得税准备金 | 9,561 | (69,033) | 48,105 | (214,750) | ||||||||||||
财产和设备的折旧 | 273,092 | 172,654 | 722,422 | 313,594 | ||||||||||||
使用权资产的摊销 | 518,873 | 133,991 | 1,441,014 | 304,027 | ||||||||||||
无形资产摊销 | 392,615 | 254,706 | 1,093,714 | 718,716 | ||||||||||||
外汇(亏损)收益 | 80 | 62,971 | (4,438) | 66,904 | ||||||||||||
其他收入 | (1,185,110) | (1,252) | (2,000,671) | (1,300) | ||||||||||||
减值准备金 | - | - | - | 5,527,913 | ||||||||||||
收益对价公允价值的变化 | - | - | (1,165,697) | 2,451,600 | ||||||||||||
或有对价公允价值的变化 | (3,542,325) | 8,053,337 | (3,269,230) | 2,659,329 | ||||||||||||
交易成本 | 72,839 | 838,957 | 607,151 | 2,407,366 | ||||||||||||
遣散费 | 315,569 | - | 544,318 | - | ||||||||||||
基于股票的薪酬 | 264,637 | 378,683 | 1,001,733 | 1,306,341 | ||||||||||||
调整后 EBITDA | $ | 749,765 | $ | 220,721 | $ | 602,300 | $ | 1,926,697 |
Additional Information
附加信息
Unless otherwise specified, all dollar amounts in this press release are expressed in Canadian dollars.
除非另有说明,否则本新闻稿中的所有美元金额均以加拿大语dollars 表示。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所风险交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
Certain statements contained in this press release constitute "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as "expects" "believes", "estimates", "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", and "anticipate", and similar expressions as they relate to the Company, including: management expecting revenue growth to continue into 2024; the Company launching new products in 2024; and the Company being in a position for continuous growth. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: increased demand for the Company's products, including at increased prices; the Company expecting the execution of additional distribution agreements; the Company expecting continued improvement with its product mix by increasing its ratio of sales of high-margin products compared to its lower margin contract manufacturing sales; and the Company expecting minimal increase to its operating, direct and variable costs during 2024. The Company cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
本新闻稿中包含的某些陈述构成1995年《私人证券诉讼改革法》和适用的加拿大证券法所指的 “前瞻性信息”。这些陈述可以通过使用前瞻性术语来识别,例如 “期望”,“相信”,“估计”,“可能”,”会”、“可以”、 “应该”、“潜在”、 “将”、“寻求”、“打算”、“计划” 和 “预测”,以及相关的类似表达to 该公司,包括: 管理层预计收入增长将持续到2024年; 公司于2024年推出新产品; 而且公司有能力持续增长。 除historical 事实陈述外,所有statementsother 都可能是前瞻性的 信息。此类陈述反映了公司目前对未来events 的看法和意图以及公司目前获得的信息,并受某些风险、uncertainties 和假设的影响,包括:对公司产品的需求增加,包括价格上涨;公司预计将执行额外的分销协议;公司预计其产品组合将持续改善与利润率较低的合同制造销售相比,其高利润产品的销售比率有所增加;该公司预计,2024年其运营、直接和可变成本的增长幅度微乎其微。公司警告说,此处包含的前瞻性陈述受重要因素的限制,这些因素可能导致实际业绩与此类陈述所反映的业绩存在重大差异。这些因素包括但不限于公司运营地区的general 业务和economicconditions;公司执行关键任务的能力whichpriorities,including 成功完成收购、业务 保留和 战略计划以及 吸引、发展and 留住关键高管;难以整合新收购的业务;ongoing 或供应链出现新的中断、此类供应链中断的程度和范围,以及解决或改善此类中断的时机或程度;能力 实施业务战略并寻求商机;disruptions 对公司信息技术、互联网、网络接入或其他方面的攻击(包括cyber-攻击)voice 或数据communications 系统或服务;公司面临的各种欺诈或其他criminal 行为的演变;第三方未能履行其对 公司或其affiliates 的义务;现行法律法规的新、变更或适用的 影响;granting 在高度监管的企业中对许可证和执照的影响;overall 艰难litigation 环境,包括美国的环境;竞争加剧;外币汇率的变化;increasedfundingcosts 以及市场流动性不足和资金竞争导致的市场波动;基金的availabilityand 用于开展运营的资源;关键accounting 估计和会计准则、政策的变化, 以及公司使用的方法;自然和非自然的发生 灾难性eventsand 索赔resulting 来自此类事件;以及所讨论的风险因素或referred 至in 向美国证券交易委员会提交的披露documentsCompanyandavailable 在www .sec.gov,还有加拿大某些省份的the 证券监管机构,available 位于。如果任何factor 以意想不到的方式影响公司,或者assumptions 标的the 前瞻性information 被证明不正确,则实际业绩或事件可能会有所不同materially 来自结果or 事件的预测。Any 本警示词在entirety 中对此类前瞻性信息进行了明确限定statement。此外,the Company 对这种外观forward 的information 的准确性或completeness 不承担任何责任。本新闻稿中包含的前瞻性信息is 截至本新闻稿date 发布release 且公司没有义务公开更新或修改any 向前发布looking 信息,other 超出适用法律的要求。
1centers-united-states/#:~:text=Questions%20Clients%20Ask%20About%20This%20Industry&text=There%20are%2048%2C698%20Physical%20Therapy,increase%20of%203.6%25%20from%202021 and
1centers-united⸺-states /#: ~: text=questions%20clients%20ask%20about%20about%20this%20industry&text=there%20are%2048 %2C 698% 20Physical%20Therapy,从 %202021 增加百分比 203.6% 25% 20 还有
译文内容由第三方软件翻译。